Asana is focusing its resources on the development of a technology to treat IBD (including ulcerative colitis and Crohn’s disease) as well as other GI diseases. Asana’s first target is ulcerative colitis (UC), to be followed by Crohn’s disease and rectal mucositis. Asana will provide physicians with a first-in-class non-drug, non-surgical treatment option for their patients suffering from ulcerative colitis.
Asana’s solution is to use a liquid form of Extracellular Matrix (ECM), called Extracellular Matrix Hydrogel (ECMH). ECM has been commercialized for over a decade and has been safely used in many clinical applications to treat millions of patients. Asana is confident that ECMH can be used to coat and protect the colon in ulcerative colitis patients, allowing the body to heal the inflamed tissue.
Extracellular Matrix Hydrogel (ECMH)
- ECM is a major structural component of the human body
- Derived from natural animal tissue
- Used in multiple commercialized clinical applications including topical and surgically-implanted forms
ECM is delivered to the colon using a standard GI procedure, creating a drug-free, surgery-free therapy to facilitate disease remission.